Patisiran
Phase 3Completed 1 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Amyloidosis
Conditions
Amyloidosis
Trial Timeline
Jul 16, 2015 → Nov 23, 2022
NCT ID
NCT02510261About Patisiran
Patisiran is a phase 3 stage product being developed by Alnylam Pharmaceuticals for Amyloidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02510261. Target conditions include Amyloidosis.
What happened to similar drugs?
0 of 11 similar drugs in Amyloidosis were approved
Approved (0) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05505838 | Pre-clinical | Completed |
| NCT05023889 | Phase 1 | Active |
| NCT04201418 | Pre-clinical | Completed |
| NCT03862807 | Phase 3 | Completed |
| NCT02510261 | Phase 3 | Completed |
| NCT01617967 | Phase 2 | Completed |
Competing Products
20 competing products in Amyloidosis